Oct 28 (Reuters) – The COVID-19 vaccine that French drugmaker Sanofi is developing with British partner GlaxoSmithKline will have a price tag of less than 10 euros, a senor executive at the company said on Thursday.
Sanofi is hoping for a comeback after falling behind rivals in the race for COVID-19 shots and is expecting to have the full results of mass trials for its planned vaccine by the end of 2021.
Thomas Triomphe, head of the Sanofi Pasteur vaccines division, told a conference call with analysts the company was aiming to produce a “practical, universal” shot that could be used as a booster to vaccines already on the market.
He said the shots would have “affordable pricing, south of 10 euros.”
Reporting by Silvia Aloisi
Editing by Peter Graff
Our Standards: The Thomson Reuters Trust Principles.